Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers.

OBJECTIVE Methamphetamine has raised concerns because it may be neurotoxic to the human brain. Although prior work has focused primarily on the effects of methamphetamine on dopamine cells, there is evidence that other neuronal types are affected. The authors measured regional brain glucose metabolism, which serves as a marker of brain function, to assess if there is evidence of functional changes in methamphetamine abusers in regions other than those innervated by dopamine cells. METHOD Fifteen detoxified methamphetamine abusers and 21 comparison subjects underwent positron emission tomography following administration of [(18)F]fluorodeoxyglucose. RESULTS Whole brain metabolism in the methamphetamine abusers was 14% higher than that of comparison subjects; the differences were most accentuated in the parietal cortex (20%). After normalization for whole brain metabolism, methamphetamine abusers exhibited significantly lower metabolism in the thalamus (17% difference) and striatum (where the differences were larger for the caudate [12%] than for the putamen [6%]). Statistical parametric mapping analyses corroborated these findings, revealing higher metabolism in the parietal cortex and lower metabolism in the thalamus and striatum of methamphetamine abusers. CONCLUSIONS The fact that the parietal cortex is a region devoid of any significant dopaminergic innervation suggests that the higher metabolism seen in this region in the methamphetamine abusers is the result of methamphetamine effects in circuits other than those modulated by dopamine. In addition, the lower metabolism in the striatum and thalamus (major outputs of dopamine signals into the cortex) is likely to reflect the functional consequence of methamphetamine in dopaminergic circuits. These results provide evidence that, in humans, methamphetamine abuse results in changes in function of dopamine- and nondopamine-innervated brain regions.

[1]  D. Kuhl,et al.  Neurochemical imaging of Alzheimer's disease and other degenerative dementias. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[2]  Linda Chang,et al.  Evidence for long-term neurotoxicity associated with methamphetamine abuse , 2000, Neurology.

[3]  Mathias Schreckenberger,et al.  Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG , 1999, Neuropsychopharmacology.

[4]  J. Larsen,et al.  The influence of fatigue on health‐related quality of life in patients with Parkinson's disease , 2003, Acta neurologica Scandinavica.

[5]  N. Volkow,et al.  Addiction and imaging of the living human brain. , 1998, Drug and alcohol dependence.

[6]  L. Radloff The CES-D Scale , 1977 .

[7]  P. Groves,et al.  Histological and ultrastructural evidence thatd-amphetamine causes degeneration in neostriatum and frontal cortex of rats , 1990, Brain Research.

[8]  Karl J. Friston,et al.  Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. , 1998, European journal of nuclear medicine.

[9]  M. Pallàs,et al.  Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats , 1998, Brain Research.

[10]  D. Brooks The early diagnosis of parkinson's disease , 1998, Annals of neurology.

[11]  Seiden Ls,et al.  Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. , 1996 .

[12]  L. Seiden,et al.  Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain , 1985, Brain Research.

[13]  D. Brunswick,et al.  Effects of high‐dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography , 1992, Synapse.

[14]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  L. Cervo,et al.  Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys , 1984, Pharmacology Biochemistry and Behavior.

[16]  D. Hovda,et al.  Administration of Excitatory Amino Acid Antagonists via Microdialysis Attenuates the Increase in Glucose Utilization Seen following Concussive Brain Injury , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  S. Walsh,et al.  Motor impairments after methamphetamine-induced neurotoxicity in the rat. , 1992, The Journal of pharmacology and experimental therapeutics.

[18]  J. Cadet,et al.  Methamphetamine (METH) causes reactive gliosis in vitro: attenuation by the ADP-ribosylation (ADPR) inhibitor, benzamide. , 1994, Life sciences.

[19]  M. Lee,et al.  A case of central pontine and extrapontine myelinolysis with early hypermetabolism on 18FDG-PET scan. , 1998, Journal of Korean medical science.

[20]  C. Meshul,et al.  High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity , 1999, Neuroscience.

[21]  W. Hays Statistics for the social sciences , 1973 .

[22]  J O Rinne,et al.  Usefulness of a dopamine transporter PET ligand [18F]β-CFT in assessing disability in Parkinson's disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[23]  L. Seiden,et al.  α-Methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex , 1986, Brain Research.

[24]  F. Fazio,et al.  Differential distribution of striatal [123I]β-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with single-photon emission tomography , 1998, European Journal of Nuclear Medicine.

[25]  N. Alpert,et al.  FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  A. Alavi,et al.  Metabolic and clinical correlates of acute ischemic infarction , 1987, Neurology.

[27]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[28]  S. Tsai,et al.  Effects of Repeated High-Dose Methamphetamine on Local Cerebral Glucose Utilization in Rats , 1999, Neuropsychopharmacology.

[29]  L. Matsuda,et al.  Neurotoxicity of amphetamines and their metabolites. , 1997, NIDA research monograph.

[30]  V. Dhawan,et al.  Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.

[31]  A. Levey,et al.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.

[32]  K. Shaw Human methamphetamine-related fatalities in Taiwan during 1991-1996. , 1999, Journal of forensic sciences.

[33]  M. Sasaki,et al.  Hyperperfusion and hypermetabolism in brain radiation necrosis with epileptic activity. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  D. Wong,et al.  Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428 , 1998, The Journal of Neuroscience.

[35]  L. Seiden,et al.  Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study , 1980, Brain Research.

[36]  D. Mash,et al.  Immunochemical analysis of dopamine transporter protein in Parkinson's disease , 1997, Annals of neurology.

[37]  G Lucignani,et al.  Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  C. Vorhees,et al.  Effect of methamphetamine on glutamate‐positive neurons in the adult and developing rat somatosensory cortex , 1996, Synapse.

[39]  S. O'dell,et al.  Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine , 1996, Synapse.